scout
Opinion|Videos|May 29, 2025

Looking Ahead For the Treatments of R/R MM

Panelists discuss how health care professionals can prepare for emerging trends in treating relapsed/refractory multiple myeloma (R/R MM) by staying informed on innovative therapies and adapting to evolving patient care strategies.

Episodes in this series

Video content above is prompted by the following:

Treatments of R/R MM

The treatment landscape for R/R MM is evolving rapidly, with new therapies on the horizon. Health care professionals must stay informed about these emerging trends to offer the best patient outcomes. Key developments include the following:

  • Novel Drug Classes and Mechanisms: New drug classes, such as BCMA-targeted therapies, bispecific antibodies, and chimeric antigen receptor T-cell therapies, are showing promise in improving responses for patients with R/R MM. Understanding their mechanisms and integration into treatment protocols is essential.
  • Personalized Treatment Approaches: Advances in genomics and molecular profiling are enabling more personalized treatment plans. Physicians should consider utilizing genetic and biomarker testing to tailor therapies that are most effective for individual patients.
  • Combination Therapies: Combining new agents with standard treatments may enhance efficacy. Physicians must remain vigilant in assessing the safety and effectiveness of these combinations.
  • Managing Adverse Effects: As newer treatments enter the market, managing novel adverse effects becomes critical. Continuous monitoring and patient education on potential adverse events will be necessary.
  • Clinical Trial Involvement: Participation in clinical trials provides patients access to cutting-edge therapies. Physicians should actively discuss trial options with eligible patients.

How Health Care Professionals Can Prepare:

  • Stay updated with ongoing clinical trials and drug approvals.
  • Gain expertise in novel therapies and their specific indications.
  • Advocate for and facilitate personalized treatment plans.
  • Be proactive in educating patients about emerging options and potential adverse effects.
  • Integrate interdisciplinary collaboration to ensure comprehensive care.

Conclusion

As the landscape of R/R MM treatments evolves, health care professionals need to be agile in their knowledge and application of emerging therapies, ensuring that patients receive the most advanced care available.

Newsletter

Stay up to date on the most recent and practice-changing oncology data


Latest CME